Sunil Solomon, MBBS, PhD, MPH

CRS:

JHU

Role:

Investigators

Position:

Investigator

Sunil Suhas Solomon, MBBS PhD MPH is a Professor of Medicine, in the Division of Infectious Diseases, at the Johns Hopkins University School of Medicine. He is also the Chairman of the YR Gaitonde Medical Educational and Research Foundation, Chennai, India. He completed his medical training at the Sri Ramachandra Medical University in Chennai, India and received a Masters in Public Health and a doctorate in Epidemiology (PhD) from the Johns Hopkins University, USA. Dr. Solomon has been elected into the Phi Beta Kappa honors society for academic excellence and the Delta Omega Public Health honors society. His research is focused on the epidemiology, clinical management and access to HIV and HCV care among vulnerable Indian populations such as people who inject drugs and men who have sex with men. He has over 100 peer-reviewed publication in several highly ranked journals such as the Lancet ID, PLOS Medicine, Lancet HIV, Clinical Infectious Diseases, American Journal of Epidemiology, Addiction and AIDS. In 2015, he was one of the first recipients of the Avenir award, a Director’s award from the National Institutes of Health, USA aimed at identifying individuals who propose high impact research and who show promise of being tomorrow's leaders in the field of drug abuse and HIV.

  • Investigator, Hepatitis TSG (Dec 2015-present)
  • Investigator, A5380
  • Chair, A5360

Categories

Leadership Committees
CRS
Roles

Clinical Trials

P2026: Pharmacokinetic Properties of Antiretroviral and...

IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women,...

Read More

A5279, Phase III Clinical Trial of Ultra-Short-Course...

This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...

Read More

HPTN083: A Phase 2b/3 Double Blind Safety and Efficacy Study...

HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for...

Read More

A5273: Multicenter Study of Options for Second-Line...

The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...

Read More

P1077BF: Breastfeeding Version of the PROMISE Study...

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More